Form 8-K · Current Report · Filed 2026-05-21
Zoetis Inc. Board Member Louise M. Parent Retires Ahead of Annual Meeting
Zoetis Inc. announced that Ms. Louise M. Parent retired from the Board of Directors on May 20, 2026, prior to the Company's 2026 Annual Meeting of Shareholders in accordance with the Company's director retirement policy. At the Annual Meeting, shareholders elected twelve directors, approved the compensation program for named executive officers, voted to hold an annual advisory vote on executive compensation, ratified the appointment of KPMG LLP as the independent registered public accounting firm, and rejected a proposal to permit shareholder action by written consent.
- Filer
- Zoetis Inc. ZTS · NYSE
- Filed
- Accession
- 0001555280-26-000029
- CIK
- 0001555280
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$79.71
Next session
+2.0%
Since filing
-3.0%
Latest close
$77.29
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ZTS reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, ZTS insiders reported 11 Form 4 transactions — net buying of $911K.
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Never miss another ZTS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.